CN101598731B - Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour - Google Patents
Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour Download PDFInfo
- Publication number
- CN101598731B CN101598731B CN 200910022400 CN200910022400A CN101598731B CN 101598731 B CN101598731 B CN 101598731B CN 200910022400 CN200910022400 CN 200910022400 CN 200910022400 A CN200910022400 A CN 200910022400A CN 101598731 B CN101598731 B CN 101598731B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cancer
- diagnosis
- hab18g
- tumour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 77
- 238000010827 pathological analysis Methods 0.000 title abstract description 7
- 238000009007 Diagnostic Kit Methods 0.000 title abstract description 6
- 239000000126 substance Substances 0.000 title abstract 2
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims abstract description 113
- 102100032412 Basigin Human genes 0.000 claims abstract description 112
- 238000003745 diagnosis Methods 0.000 claims abstract description 57
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 16
- 230000001575 pathological effect Effects 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 239000012916 chromogenic reagent Substances 0.000 claims abstract description 9
- 229960002685 biotin Drugs 0.000 claims abstract description 8
- 235000020958 biotin Nutrition 0.000 claims abstract description 8
- 239000011616 biotin Substances 0.000 claims abstract description 8
- 239000002981 blocking agent Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 54
- 239000003550 marker Substances 0.000 claims description 54
- 230000002055 immunohistochemical effect Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 10
- 108010090804 Streptavidin Proteins 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000004043 dyeing Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000013016 damping Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003593 chromogenic compound Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 238000010186 staining Methods 0.000 claims description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- -1 reacted 10 minutes Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 abstract description 45
- 201000007270 liver cancer Diseases 0.000 abstract description 16
- 208000014018 liver neoplasm Diseases 0.000 abstract description 16
- 238000004393 prognosis Methods 0.000 abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 10
- 201000005202 lung cancer Diseases 0.000 abstract description 10
- 208000020816 lung neoplasm Diseases 0.000 abstract description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 9
- 206010006187 Breast cancer Diseases 0.000 abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 7
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 5
- 238000013399 early diagnosis Methods 0.000 abstract description 5
- 238000007789 sealing Methods 0.000 abstract description 5
- 210000000981 epithelium Anatomy 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 108090001008 Avidin Proteins 0.000 abstract description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000035999 Recurrence Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000000498 stomach carcinoma Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 208000019065 cervical carcinoma Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004797 therapeutic response Effects 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000005034 decoration Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000012308 immunohistochemistry method Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000009184 Neoplasms by Histologic Type Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an immune tissue chemical diagnostic kit of HAb18G/CD147 cancer landmark used for pathological diagnosis of tumour, including a blocking agent capable of removing endogenous enzyme in a human tissue slice, a sealing agent used for sealing cross protein reaction in the human tissue slice, a first antibody capable of combining with the HAb18G/CD147 cancer landmark in human tumour tissue, a biotin marked secondary antibody capable of combining with the first antibody, and an enzyme marked avidin, chromogenic reagent and a phosphate buffer system used for combining with the secondary antibody. The kit has the characteristics of good specificity, high sensibility, stability and universality, is mainly used for pathologic diagnosis of epithelium-derived malignant tumour (such as liver cancer, lung cancer, esophageal cancer, gastric cancer, colorectal cancer, breast cancer, cervical cancer, ovarian cancer and the like), and is beneficial to warning screen, early diagnosis, etiologic diagnosis, treatment reaction and curative effect monitoring of tumour, recrudescence and transfer and prognosis judgement of tumour.
Description
Technical field
The invention belongs to bioengineering field, relate to a kind of kit for clinical diagnosis, particularly a kind of immunohistochemical diagnosis kit of the HAb18G/CD147 carcinoma marker for the pathologic diagnosis of tumor purposes.
The HAb18G/CD147 carcinoma marker is a kind of novel, wide spectrum and than the carcinoma marker of high specific, with a kind of specific antibody for the HAb18G/CD147 carcinoma marker, in conjunction with general ImmunohistochemistryMethods Methods, make HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit, be applied to multiple human cancers histopathology sample, carry out pathologic diagnosis of tumor, help early warning screening, early diagnosis, etiologic diagnosis, therapeutic response and the curative effect monitoring of tumour, relapse and metastasis and the prognosis of tumour to judge.
Background technology
In recent years, the number of the infected of various tumours is all in rapid rising, and the medical expense of tumour and the death of tumor patient cause white elephant all can for society and family.People are in the urgent need to the diagnosis that can be used for tumour and technological means or the method for the treatment of.Current, the 3P medical science take prospective medicine, preventive medicine and Personalized medicine as core has become assurance, has improved the important directions of level of human health, and the discovery and application of carcinoma marker is the important key that realizes 3P medical science.
Carcinoma marker (tumor marker) is to be present in the tumour cell or by a kind of material of its secretion, can be distributed in blood, tissue fluid, secretion or the tumour cell.The variation of carcinoma marker and the generation of tumour, development and prognosis have direct relation, as point out the character of tumour, the tissue of understanding tumour occurs, Cell Differentiation, help early warning screening, early diagnosis, etiologic diagnosis, therapeutic response and the curative effect monitoring of tumour, relapse and metastasis and the prognosis of tumour to judge, help diagnosis, molecule parting and the individualized treatment of tumour to instruct.
In recent years, because the fast development of biotechnology, the discovery and application of novel tumor mark has been accelerated in the application of monoclonal antibody technology, protein science technology, bioinformatics greatly.Its technical foundation mostly is by with antibody screening tumour cell chip, cDNA expression library, the methods such as combining yeast double cross, co-immunoprecipitation, mass-spectrometric technique, catch this antibody for antigen molecule.The discovery and application of novel tumor mark has vital role to setting up Prognosis scoveillances such as tumour early warning examination, early diagnosis, etiologic diagnosis, therapeutic response and transfer and relapse etc.
SABC is to utilize the principle of antigen and antibody specific binding, make developer (fluorescein, enzyme, metallic ion, the isotope) colour developing of labelled antibody determine histocyte endoantigen (peptide and protein) by chemical reaction, to its position, qualitative and quantitative research.At present immunohistochemistry widespread use diagnose with clinicopathologia, particularly carry out tumour auxiliary diagnosis and antidiastole with antibody pointedly, become clinicopathologia and diagnose indispensable important means.
The HAb18G/CD147 molecule is a kind of novel carcinoma marker, and this molecule is the transmembrane glycoprotein of 61kDa, by the molecule that 269 amino acid form, is to screen acquisition with specific monoclonal antibody in human liver cancer cell cDNA expression library.Its monoclonal antibody is the HAb18 (patent No.: ZL02114471.0), be with Freshman liver cancer tissue cell suspension immunity Bab1/C mouse, be prepared from hybridoma technology.
HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit, be used for pathologic diagnosis of tumor, identify through SABC tissue spectrum, this molecule is high expressed in multiple cancerous tissue, extremely low expression in normal structure and embryonic tissue, be distributed with better specificity, the dyeing phenotype is membranous type or film slurry type.
71.4%), liver cancer (positive rate: 80.0%), cancer of the stomach (positive rate: 68%), lung cancer (positive rate: 54.3%) ImmunohistochemistryResults Results of 2006 routine organization chips shows that the expression rate of HAb18G/CD147 carcinoma marker in following cancer is: breast cancer (positive rate:.And in normal liver tissue, adenoma of liver pathological tissues, express for low; Normal structure, benign tumour and benign disease tissues at mammary gland are negative.Use the responsive Immunohistochemical Staining of multiple height such as ABC-APAAP, the liver cancer tissue section is observed distribution and the location of HAb18G in light microscopic and two levels of Electronic Speculum, the result show the HAb18G/CD147 carcinoma marker optionally high expressed in liver cancer tissue, its positive rate is 75% (39/52), and normal liver tissue is low expresses.Immuno-electron microscope (collaurum) is positioned on the elementary membrane of hepatoma cell membrane, endoplasmic reticulum and envelope shape structure.Result of study is published in Proteomics, and 7 (13): 2151-2161,2007; Histopathology, 2008.
The appearance of monoclonal antibody and the development continuously and healthily of immunohistochemistry detection system make the application of immunohistochemistry technology in modern pathological diagnosis increasingly extensive, and are subjected to the concern and blue or green fan of pathology circle.The earliest with the initial stage seventies only in the laboratory scientific research attempt, went through for 30 years after this technology developed into requisite reliable auxiliary diagnosis means in the routine pathology diagnosis.
In the routine pathology diagnosis, most of cases are to make clear and definite Morphologic Diagnosis in the section of HE dyeing, the case of difficult and problem are arranged at 5-10%.Further diagnosis mainly by specific antibody dyeing, is done to the clinical pathology histotomy by immunohistochemistry technology, analyzes the relation of tumor markers, tumor associated antigen and disease, improves the accuracy of pathological diagnosis with auxiliary diagnosis.
The related neoplasms mark antibody of present clinical use has more than 100 to plant, and the antibody of diagnosing tumor commonly used has 10 kinds approximately, and antibody is used in many genus researchs, mainly is to sell from buying rear packing abroad.Without regular lot number, differ greatly between the antibody of in pathological diagnosis, using and antibody batch, repeatable poor, result not person of modern times anticipates.
Summary of the invention
The object of the invention is to, a kind of immunohistochemical diagnosis kit of the HAb18G/CD147 carcinoma marker for the pathologic diagnosis of tumor purposes is provided.This diagnostic kit is the biological characteristics that utilizes the Ag-Ab specific binding, with the HAb18 specific monoclonal antibody clinical pathology tissue specimen is dyeed, by the SP ImmunohistochemistryMethods Methods, observe the expression of HAb18G/CD147 carcinoma marker in human cancers, clinical practice is in auxiliary diagnosis or the antidiastole of human cancers.This kit has the advantages that specificity is good, susceptibility is high, stable, general.
In order to realize above-mentioned task, the present invention takes following technical solution:
A kind of immunohistochemical diagnosis kit of the HAb18G/CD147 carcinoma marker for the pathologic diagnosis of tumor purposes is characterized in that the content of this kit comprises:
1) be used for to remove the blocking agent of people's histotomy endogenous enzyme, this blocking agent is that 3% superoxol and concentration are that 80% methanol solution forms by concentration;
2) for the nonspecific proteins sealer that seals people's histotomy intersection albumino reaction unspecific staining; This sealer is formulated by 3-5% Normal animal serum and phosphate buffer;
3) first antibody that the HAb18G/CD147 carcinoma marker is combined in human body cancer tissue; This first antibody is the mouse monoclonal antibody of specific binding HAb18G/CD147 carcinoma marker, and its working concentration is 10-100 μ g/mL;
4) second antibody that can be combined with first antibody; This second antibody is the polyclonal antibody of biotin labeled sheep or the anti-mouse IgG of rabbit;
5) be used for enzyme mark Streptavidin in conjunction with biotin on the second antibody; This enzyme mark Streptavidin is the Streptavidin of horseradish peroxidase-labeled, is chromogenic substrate;
6) with the chromogenic reagent of chromogenic substrate effect, this chromogenic reagent is that benzidine (DAB) solution, trishydroxymethylaminomethane (TrisHcl) damping fluid and deionized water are formulated, more than the preparation consumption volume ratio of three kinds of reagent be 1: 1: 50.
7) the used buffer system of kit is phosphate buffer Na
2HPO
4-NaH
2PO
4-NaCl, concentration is 0.01mol/L, pH is 7.2～7.45.
Above-mentioned first antibody is preserved in the liquid at the antibody of 10-100 μ g/mL concentration and is preserved, and this antibody is preserved liquid can keep antibody 2-8 ℃ of lower the preservation 24 months.
The technical characterstic of the HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit for the pathologic diagnosis of tumor purposes of the present invention is:
1, the first antibody in this kit is the antibody of a high specific, broad spectrum activity.The HAb18G/CD147 tumor markers is to screen acquisition with first antibody in human liver cancer cell cDNA expression library, and HAb18G/CD147 confirms that through to this analysis of the molecular structure molecule is the transmembrane glycoprotein of 61kDa, is comprised of 269 amino acid; Through inquiry Genbank, this molecule is identical with people CD147 gene coded sequence, is positioned No. 19 chromosomes of people, is the member of immunoglobulin superfamily.A large amount of fundamental researchs and applied research working foundation have disclosed biological function and the application value of this tumor markers specific antibody deeply.
2, the immunohistochemical diagnosis kit of this HAb18G/CD147 carcinoma marker, be applicable to people's tissue specimen, fix paraffin-embedded tissue specimen slice with 10% neutral formalin solution, with the cancerous tissue sample of excision, the frozen section of making immediately.
3, in this kit, phosphate buffer system (0.01mol/L, Na that the applicant adopts
2HPO
4-NaH
2PO
4-NaCl, pH 7.2～7.45) consistance and accuracy in whole immunohistochemical experiment procedure, effectively controlled the nonspecific reaction background.
4, in this kit, the first antibody that the applicant adopts is preserved liquid, and its characteristics are preserved liquid for this antibody and contained bovine serum albumin(BSA), collagen, phosphate buffer and NaN
3, this antibody is preserved liquid can keep antibody function, preserves 24 months at 2-8 ℃.Guaranteed the stability of key reagents in the method.
It is good that above technical characterstic has guaranteed that HAb18G/CD147 carcinoma marker SABC kit has specificity, and susceptibility is strong, the characteristic of good stability, simple general-purpose.Use by many hospitals, sheet is read in the dyeing of clinical more than 2000 routine tumor tissues samples, the result shows, HAb18G/CD147 carcinoma marker wide expression (comprises lung cancer in the malignant tumour of epithelium source property, the cancer of the esophagus, cancer of the stomach, colorectal cancer, liver cancer, breast cancer, oophoroma, cervical carcinoma etc.) tissue, the low expression in normal structure and benign disease tissues, also present expression trend in the more other tissue of atypical hyperplasia of cancer and active proliferation sexual cell, it is a kind of novel pointing out this mark, wide spectrum, than the carcinoma marker of high specific, this kit is that diagnosing tumor and prognosis are judged, new approaches and methods has been opened up in assessment.
Description of drawings
Fig. 1 is the colouring method synoptic diagram of HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit;
Fig. 2 is that the present invention is at different tumor tissues, the microscopically HAb18G/CD147 carcinoma marker SABC kit coloration result collection of illustrative plates of normal structure, wherein (A), the liver cancer tissue of embodiment 1 and the microscopically HAb18G/CD147 carcinoma marker SABC kit coloration result collection of illustrative plates of normal structure, (B) being the cancerous lung tissue of embodiment 2 and the microscopically HAb18G/CD147 carcinoma marker SABC kit coloration result collection of illustrative plates of normal structure, (C) is the human esophageal carcinoma of embodiment 3 and the microscopically HAb18G/CD147 carcinoma marker SABC kit coloration result collection of illustrative plates of normal structure.
The embodiment that provides below in conjunction with accompanying drawing and inventor is described in further detail the present invention.
Embodiment
HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit for aided Cancer Diagnosis or antidiastole of the present invention, be mainly used in the pathological diagnosis of human cancers (liver cancer, lung cancer, the cancer of the esophagus, cancer of the stomach, colorectal cancer, breast cancer, cervical carcinoma, oophoroma etc.), help early diagnosis, etiologic diagnosis, therapeutic response and the curative effect monitoring of tumour, relapse and metastasis and the prognosis of tumour to judge.Comprise in this kit content:
1, be used for removing the blocking agent of people's histotomy endogenous enzyme, is that 3% superoxol and concentration are that 80% methanol solution preparation in 1: 10 by volume forms by concentration;
2, the nonspecific proteins sealer that is used for sealing people histotomy intersection albumino reaction unspecific staining; This sealer is formulated by 3-5% Normal animal serum and phosphate buffer;
3, first antibody, this first antibody are the mouse monoclonal antibodies of specific binding HAb18G/CD147 carcinoma marker, and its working concentration is 10-100 μ g/mL; This HAb18G/CD147 carcinoma marker high expressed is in the malignant tumour of epithelium source property, and they are liver cancer, lung cancer, the cancer of the esophagus, cancer of the stomach, the carcinoma of the rectum, breast cancer, cervical carcinoma, oophoroma or other known cancer;
4, the second antibody that can be combined with first antibody; This second antibody is the polyclonal antibody of biotin labeled sheep or the anti-mouse IgG of rabbit;
5, be used for enzyme mark Streptavidin in conjunction with biotin on the second antibody; The connection enzyme avidin that this enzyme mark Streptavidin is horseradish peroxidase-labeled is chromogenic substrate;
6, with the chromogenic reagent of chromogenic substrate effect, this chromogenic reagent is that benzidine (DAB) solution, trishydroxymethylaminomethane (TrisHcl) damping fluid and deionized water are formulated, more than the preparation consumption volume ratio of three kinds of reagent be 1: 1: 50.
7, the used buffer system of kit is phosphate buffer Na
2HPO
4-NaH
2PO
4-NaCl, concentration is 0.01mol/L, pH is 7.2～7.45.
First antibody is preserved in the liquid at the antibody of 10-100 μ g/mL concentration and is preserved, and can keep antibody function, preserves 24 months at 2-8 ℃.Antibody is preserved liquid and is contained 1% bovine serum albumin(BSA), 0.1% collagen, 0.01mol/L phosphate buffer, 0.05%NaN
3
The colouring method of HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit, its principle schematic be as shown in Figure 1:
People's histotomy with aquation after, add an amount of endogenous enzyme blocking agent, reacted 10 minutes, phosphate buffer cleans; Drip 1～2 of nonspecific proteins sealer, reacted 10 minutes; Drip 1～2 of first antibody, 37 ℃ were reacted 2 hours, and phosphate buffer cleans; Drip 1～2 of second antibody, 22-28 ℃ was reacted 20 minutes, and phosphate buffer cleans; Drip 1～2 of enzyme mark streptavidin, 22-28 ℃ was reacted 15 minutes, and phosphate buffer cleans; Drip 1～2 of freshly prepared chromogenic reagent, 22-28 ℃ was reacted 1～10 minute, and phosphate buffer cleans; Bush uniformly dyeing nuclear, gradient alcohol dehydration, dimethylbenzene are transparent, neutral gum mounting, observation by light microscope.Above-mentioned phosphate buffer cleans and is that concussion was cleaned 5 minutes each 3 times.
Phosphate buffer is Na
2HPO
4-KH
2PO
4-NaCl, concentration is 0.01mol/L, pH is 7.2～7.45.But the dyeing background of this phosphate buffer balanced reaction pH of system value, minimizing non-specific responding.
Immunohistochemistry technology is an experimental very strong technology, and its key elements of success mainly contains the antibody that specificity is good, broad spectrum activity is good, reliable reagent and experimental technique, strict quality control requirement.
Below be the specific embodiment that the inventor provides:
HAb18G/CD147 carcinoma marker immunodiagnosis reagent kit experimental technique is as follows, and following examples are called for short " experimental technique " all with reference to the method:
1, clinical tissue case paraffin specimen section, dimethylbenzene dewaxing 20min, 3 times;
2,100% alcohol is sloughed dimethylbenzene, 5min, 2 times; 95%～75% alcohol, 2min/ time;
3,3%H2O2 sealing endogenous peroxydase, 22-28 ℃, 10 minutes;
4, the PBS damping fluid embathed 3 minutes, 3 times;
5, non-specific site in the 5% normal sheep serum sealing tissue, 22-28 ℃, 20 minutes;
6, HAb18 monoclonal antibody (30ug/mL), 37 ℃, 120 minutes;
7, the PBS damping fluid embathed 5 minutes, 3 times;
8, the anti-specificity antiantibody of avidin mark, 22-28 ℃, 15 minutes;
9, the PBS damping fluid embathed 5 minutes, 3 times;
10, horseradish peroxidase-labeled biotin, 22-28 ℃, 20 minutes;
11, the PBS damping fluid embathed 5 minutes, 3 times;
12, DAB colour developing, 22-28 ℃, 2-10 minute;
13, haematine lining transfect cell nuclear, 22-28 ℃, 5 minutes;
14,5%～95% alcohol, 2min/ time; 100% dehydration of alcohol, 5min, 2 times;
15, dimethylbenzene is transparent, 5min, 2 times; Microscopic examination.
The selection of research object: with goldstandard HE decoration method, as the pacing items of determining case group and control group sample, according to the histopathology morphological feature, determine to select research object.
Embodiment 1:
The HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit that is used for aided Cancer Diagnosis or antidiastole is as follows in the concrete process of the test of hepatic tissue expression:
1. sample is selected: (liver cancer, case is determined in dyeing according to goldstandard HE)
Table 1 liver cancer and hepatic tissue case are selected
2. test operation: see " experimental technique " for details.
3. test findings: (seeing accompanying drawing 2A)
The coloration result of table 2HAb18G/CD147 carcinoma marker diagnostic kit in liver cancer and hepatic tissue
Embodiment 2:
The HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit that is used for aided Cancer Diagnosis or antidiastole is as follows in the concrete process of the test of lung tissue expression:
1. sample is selected: lung cancer, the result determines case according to goldstandard HE decoration method
Table 3: lung cancer and lung tissue case are selected
2. test operation: see " experimental technique " for details.
3. test findings: (seeing accompanying drawing 2B)
The coloration result of table 4:HAb18G/CD147 carcinoma marker diagnostic kit in lung cancer and lung tissue
Embodiment 3:
The HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit that is used for aided Cancer Diagnosis or antidiastole is as follows in esophageal tissue's concrete process of the test of expression:
1. sample is selected: the cancer of the esophagus, the result determines case according to goldstandard HE decoration method
Table 5 cancer of the esophagus and esophageal tissue's case are selected
2. test operation: see " experimental technique " for details.
3. test findings: (seeing accompanying drawing 2C)
The coloration result of table 6:HAb18G/CD147 carcinoma marker diagnostic kit in the cancer of the esophagus and esophageal tissue
HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit for aided Cancer Diagnosis or antidiastole of the present invention also can be used for the detection of the expression of other various cancerous tissue HAb18G/CD147 tissues.Method sees " experimental technique " for details.
Below be to adopt the HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit for aided Cancer Diagnosis or antidiastole of the present invention in the Coloration experiment result of kinds of tumors tissue and benign disease.
Conclusion: the immunohistochemical diagnosis kit that uses the HAb18G/CD147 carcinoma marker for pathologic diagnosis of tumor of the present invention, carry out immunohistochemical staining and can obtain good coloration result, its cell membrane positive staining is clear and definite, clear, almost without unspecific staining, can obtain accurately judged result.
The immunohistochemical diagnosis kit of the HAb18G/CD147 carcinoma marker for the pathologic diagnosis of tumor purposes of the present invention, adopt the ultimate principle of the specific bond of immunology antigen and antibody " one to one ", with specificity HAb18 antibody tissue is dyeed, by distribution and the expression of HAb18G/CD147 carcinoma marker in tissue, the relation of further clear and definite HAb18G/CD147 carcinoma marker and cancer; Use the SP Immunohistochemical Method, make the multistage amplification of antigen-antibody reaction signal, the susceptibility that detects to improve the HAb18G/CD147 carcinoma marker.Therefore, HAb18G/CD147 carcinoma marker immunodiagnosis reagent kit is the specific reaction by PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM and HAb18G/CD147 carcinoma marker, to improve the accuracy of pathological diagnosis, the character of tumour is judged in research, analyze the possibility of tumour origin, and the assessment of prognosis and treatment is all had great importance.
HAb18G/CD147 carcinoma marker immunodiagnosis reagent kit is on probation many clinical disease natural sciences, sheet is read in dyeing by more than 2000 routine clinical tumor tissue specimens, the result shows, HAb18G/CD147 molecule wide expression is in malignant tumour (comprising lung cancer, the cancer of the esophagus, cancer of the stomach, colorectal cancer, liver cancer, breast cancer, oophoroma, the cervical carcinoma etc.) tissue of epithelium source property, in normal structure and the low expression of benign disease tissues, also present expression trend at the other atypical hyperplasias of some cancers, active proliferation cell.As, lung cancer specificity 90%, sensitivity 89.8%; Cancer of the esophagus specificity 93.6%, sensitivity 90.2%; Cancer of the stomach specificity 76%, sensitivity 68%; Breast cancer specificity 83.5%, sensitivity 71.4%; Liver cancer specificity 68%, sensitivity 80.0%; Colorectal cancer specificity 96%, sensitivity 57.9%.The clinical research data show the HAb18G/CD147 molecule be a kind of novel, have broad spectrum activity and than the tumor markers of high specific.HAb18G/CD147 carcinoma marker immunohistochemical diagnosis kit can help types of organization, the tumor-localizing of pathologist diagnosing tumour, the dynamic change of reflection tumour, and judging prognosis, antidiastole tumour/non-Neoplasms by histologic type and characteristics.Make that tumor patient can obtain timely, early stage, correct diagnosis, timely and effectively treatment, and help the patient to the judgement of prognosis curative effect.
HAb18G/CD147 carcinoma marker immunodiagnosis reagent kit compares with Diagnostic Value of Several Serum Tumor Markers associated antibodies and the kit (such as AFP, CEA, CA15-3, CA199, CA125, Her-2, ER, PR etc.) of at present clinical practice, embody tumour and express wide spectrum, sensitivity, specificity height, have high clinical value and wide market application foreground, can be pathologic diagnosis of tumor and prognosis and judge a kind of wide spectrum, new product comparatively accurately are provided.
Claims (2)
1. immunohistochemical diagnosis kit that is used for the HAb18G/CD147 carcinoma marker of pathologic diagnosis of tumor purposes, clinical practice is characterized in that in auxiliary diagnosis or the antidiastole of human cancers the content of this kit comprises:
1) be used for to remove the blocking agent of people's histotomy endogenous enzyme, this blocking agent is that 3% superoxol and concentration are that 80% methanol solution forms by concentration;
2) for the nonspecific proteins sealer that seals people's histotomy intersection albumino reaction unspecific staining; This sealer is formulated by 3-5% Normal animal serum and phosphate buffer;
Described people's histotomy is paraffin section and frozen section;
3) first antibody that the HAb18G/CD147 carcinoma marker is combined in human body cancer tissue; This first antibody is the mouse monoclonal antibody of specific binding HAb18G/CD147 carcinoma marker, and its working concentration is 10-100 μ g/mL;
Described first antibody is preserved in the liquid at the antibody of 10-100 μ g/mL concentration and is preserved, and this antibody is preserved liquid and included 1% bovine serum albumin(BSA), 0.1% collagen, 0.01mol/L phosphate buffer, 0.05% NaN
3, this antibody is preserved liquid can keep first antibody 2-8 ℃ of lower the preservation 24 months;
4) second antibody that can be combined with first antibody; This second antibody is the polyclonal antibody of biotin labeled sheep or the anti-mouse IgG of rabbit;
5) be used for enzyme mark Streptavidin in conjunction with biotin on the second antibody; This enzyme mark Streptavidin is the Streptavidin of horseradish peroxidase-labeled, is chromogenic substrate;
6) with the chromogenic reagent of chromogenic substrate effect, this chromogenic reagent is that benzidine (DAB) solution, trishydroxymethylaminomethane (TrisHcl) damping fluid and deionized water are formulated, more than the preparation consumption volume ratio of three kinds of reagent be 1:1:50;
7) the used buffer system of kit is phosphate buffer Na
2HPO
4-NaH
2PO
4-NaCl, concentration is 0.01mol/L, pH is 7.2 ~ 7.45.
2. the immunohistochemical diagnosis kit of the HAb18G/CD147 carcinoma marker for the pathologic diagnosis of tumor purposes claimed in claim 1 is characterized in that at the colouring method of multiple cancerous tissue, comprising:
People's histotomy with aquation after, add an amount of endogenous enzyme blocking agent, reacted 10 minutes, phosphate buffer cleans; Drip 1 ~ 2 of nonspecific proteins sealer, reacted 10 minutes; Drip 1 ~ 2 of first antibody, 37 ℃ were reacted 2 hours, and phosphate buffer cleans; Drip 1 ~ 2 of second antibody, 22-28 ℃ was reacted 20 minutes, and phosphate buffer cleans; Drip 1 ~ 2 of enzyme mark streptavidin, 22-28 ℃ was reacted 15 minutes, and phosphate buffer cleans; Drip 1 ~ 2 of freshly prepared chromogenic reagent, 22-28 ℃ was reacted 1 ~ 10 minute, and phosphate buffer cleans; Bush uniformly dyeing nuclear, gradient alcohol dehydration, dimethylbenzene are transparent, neutral gum mounting, observation by light microscope; Above-mentioned phosphate buffer cleans and is that concussion was cleaned 5 minutes each 3 times.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910022400 CN101598731B (en) | 2009-05-07 | 2009-05-07 | Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910022400 CN101598731B (en) | 2009-05-07 | 2009-05-07 | Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101598731A CN101598731A (en) | 2009-12-09 |
| CN101598731B true CN101598731B (en) | 2013-04-24 |
Family
ID=41420236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910022400 Active CN101598731B (en) | 2009-05-07 | 2009-05-07 | Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101598731B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102277334B (en) * | 2011-06-28 | 2013-10-23 | 南方医科大学 | Monoclonal antibody resisting human protein RN181, as well as hybridoma cell line 3953 and kit |
| CN102268409B (en) * | 2011-06-28 | 2013-10-23 | 南方医科大学 | Monoclonal antibody against human protein RN181 and hybridoma cell strain 3952 and kit |
| CN102435734A (en) * | 2011-09-08 | 2012-05-02 | 大连医科大学 | Ovarian cancer primary chemotherapy sensitivity evaluation kit and application thereof |
| WO2013038306A1 (en) * | 2011-09-13 | 2013-03-21 | Koninklijke Philips Electronics N.V. | System and kit for preparing a cytological sample for examination |
| CN102435735B (en) * | 2011-10-09 | 2014-01-01 | 武汉康迈生物技术有限公司 | Immunohistochemical staining detection kit for colorectal cancer and application thereof |
| CN103772505B (en) * | 2013-12-18 | 2014-10-15 | 长春博迅生物技术有限责任公司 | Antibody reagent preserving fluid |
| KR20170099737A (en) | 2016-02-23 | 2017-09-01 | 노을 주식회사 | Contact-type staining patch and staining method using the same |
| US10371610B2 (en) | 2016-02-23 | 2019-08-06 | Noul Co., Ltd. | Contact-type patch, staining method using the same, and manufacturing method thereof |
| CN108261544B (en) * | 2016-12-30 | 2023-05-05 | 江苏太平洋美诺克生物药业股份有限公司 | Stable pharmaceutical formulation comprising CD147 monoclonal antibody |
| CN108261391B (en) * | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | Stable pharmaceutical formulation comprising CD147 monoclonal antibody |
| CN106919801B (en) * | 2017-03-08 | 2023-07-18 | 杭州大伽信息科技有限公司 | Immunohistochemical staining auxiliary analysis system and use method |
| CN111551546B (en) * | 2020-06-01 | 2023-01-03 | 南京瑟斯检测科技有限公司 | Immunohistochemical convenient detection method based on optical microcavity structure metamaterial |
| CN112379093B (en) * | 2020-10-22 | 2023-06-16 | 上海良润生物医药科技有限公司 | Application of CST-Cathepsin complex as tumor diagnosis marker |
| CN113295871B (en) * | 2021-07-02 | 2023-07-21 | 河南赛诺特生物技术有限公司 | Cocktail immunohistochemical kit for diagnosing breast cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381461A (en) * | 2002-03-15 | 2002-11-27 | 陈志南 | Light chain or heavy chain variable region gene of human liver cancer monoclonal antibody HAb18 and its application |
-
2009
- 2009-05-07 CN CN 200910022400 patent/CN101598731B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381461A (en) * | 2002-03-15 | 2002-11-27 | 陈志南 | Light chain or heavy chain variable region gene of human liver cancer monoclonal antibody HAb18 and its application |
Non-Patent Citations (3)
| Title |
|---|
| 曲鑫.CD147、MMP-9、VEGF在垂体瘤中的表达及与生物学行为关系的研究.《山东大学硕士学位论文》.2009, * |
| 杨延冬.原癌基因c-Mct和分子CD147在子宫内膜癌中的表达及其临床意义.《青岛大学硕士学位论文》.2006, * |
| 陈志南等.肝癌单克隆抗体HAb18相应膜蛋白抗原在组织中的分布和亚细胞定位.《第四军医大学学报》.1992,第13卷(第1期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101598731A (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101598731B (en) | Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour | |
| CN104634974B (en) | Detection, the discriminating conduct of intrahepatic cholangiocarcinoma | |
| US10788484B2 (en) | Apparatus and method for absolute quantification of biomarkers for solid tumor diagnosis | |
| JP5221381B2 (en) | Use of HE4 and other biochemical markers to determine ovarian cancer | |
| KR101976219B1 (en) | Biomarker for breast cancer | |
| Ghods et al. | High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma | |
| Pértega‐Gomes et al. | Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer | |
| EP2329261B1 (en) | Prostate cancer biomarker | |
| CN106771248B (en) | High-level serous ovarian cancer diagnosis and/or the marker of Index for diagnosis | |
| Taeb et al. | Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients | |
| CN107001437A (en) | The inspection method and inspection medicine of ovary clear cell adenocarcinoma | |
| CN109975549A (en) | Purposes of the tumour source IgG in diagnosis of pancreatic cancer or prognosis | |
| KR20130046457A (en) | Newly identified colorectal cancer marker genes, proteins translated from the genes and a diagnostic kit using the same | |
| CN102803968B (en) | Esophageal cancer marker | |
| CN110139656A (en) | The Keratin 17 of biomarker as bladder cancer | |
| Høgdall et al. | Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish ‘MALOVA’ovarian cancer study | |
| CN109085359A (en) | Serum protein markers combine the application in colorectal cancer screening and diagnosis and treatment | |
| TWI490230B (en) | Oligopeptide specific for ovary cancer and applications thereof | |
| Baskaran et al. | Expression of matrix metalloproteinase-21 in oral squamous cell carcinoma | |
| Charpin et al. | Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival. | |
| Gromov et al. | Proteomic strategies in bladder cancer: From tissue to fluid and back | |
| US20050130241A1 (en) | Immunological detection of prostate diseases and prostasome-related conditions | |
| Polak et al. | Immunocytochemistry today: Techniques and practice | |
| CN108732352A (en) | A kind of method that five kinds of biomarker antibody of joint-detection are used to detect breast cancer | |
| Deliu et al. | Utility of tumor markers as a diagnostic tool |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: CHEN ZHINAN Effective date: 20140930 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140930 Address after: 710032 Changle West Road, Shaanxi, China, No. 17, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032, Xi'an 17, Changle West Road, Shaanxi, China Patentee before: Chen Zhinan |